VTRS Chart

1 Month

	Date	Diff
	2025-01-16	-0.44 %
Viatris Inc. (NASDAQ:VTRS) saw a 2.82% decline in its stock price, closing at $11.39, due to investor sell-off triggered by analyst comments about the stock entering oversold territory, compounded by negative sentiment surrounding the planned closure of its manufacturing plant in Ireland.
	2025-01-06	-2.69 %
Viatris (VTRS) stock went down by -2.69% likely due to concerns surrounding medication shortages and regulatory challenges impacting the pharmaceutical sector, particularly in the diabetes treatment market.
	2024-12-24	-0.72 %
Viatris (VTRS) stock fell by 0.72% amid scrutiny over a judge’s financial ties to the healthcare industry, raising concerns about potential conflicts of interest in a high-profile case involving healthcare criticism. The decline is likely influenced by the controversy surrounding the judge's investments, reflecting broader concerns about integrity and the healthcare sector. Viatris (VTRS) stock declined by 0.72% due to concerns over potential conflicts of interest involving the judge overseeing a high-profile case related to the shooting of UnitedHealthcare’s CEO, which has sparked scrutiny of the pharmaceutical industry.
	2024-11-29	-0.98 %
Viatris (VTRS) stock experienced a decline of 0.98% due to a challenging market environment and competition from other pharmaceutical companies, as highlighted by comparative analyses between Revance Therapeutics and AstraZeneca, where the latter showed stronger revenues and earnings.
	2024-11-07	+13.52 %
Viatris (VTRS) stock surged by 13.52% due to positive market sentiment and investor confidence amidst broader stock market fluctuations and forthcoming corporate developments. The increase in Viatris stock can be attributed to favorable market perceptions and potential growth factors regarding the company's operations and strategic direction.
	2024-10-28	+2.8 %
Viatris (VTRS) stock rose 2.8% due to factors such as strong institutional ownership indicating confidence from large investors, and its collaboration with Revance Therapeutics, which is advancing in various drug developments, potentially enhancing future growth prospects.
	2024-10-15	+3.95 %
Viatris (VTRS) stock rose by 3.95% likely due to speculation surrounding a potential favorable regulatory environment for cryptocurrencies if former President Donald Trump wins the upcoming presidential election, which may influence investor sentiment positively towards companies linked to the digital asset sector.
	2024-10-07	-2.24 %
Viatris (VTRS) stock fell by 2.24% due to the recall of specific batches of the blood pressure medication trandolapril after tests revealed variability in its content, leading to concerns around the product's reliability.
	2024-09-30	+0.52 %
Viatris (VTRS) stock rose by 0.52% amidst a turbulent Indian stock market characterized by significant sell-offs, likely due to factors such as its underlying business performance, investor sentiment, and market fluctuations that may have favored picking up undervalued shares within a generally declining context.
	2024-09-17	+0.08 %
Viatris (VTRS) stock was up 0.08% due to investor optimism regarding the potential sale of Bausch + Lomb, which could enhance shareholder value and resolve existing debt issues for Bausch Health, Viatris's significant stakeholder.
	2024-09-04	-0.93 %
Viatris (VTRS) stock decreased by -0.93% due to concerns about the broader financial landscape and investor sentiment amidst a challenging market environment for associated companies like Ocuphire Pharma, which has faced significant stock price declines and uncertain future performance despite some positive developments.